Combination of Omalizumab and Dupilumab for the Treatment of Severe Bullous Pemphigoid: a Series of 6 Cases
DOI:
https://doi.org/10.2340/actadv.v105.43637Keywords:
bullous pemphigoid, biotherapy, Biologics, Dupilumab, omalizumabDownloads
References
Akbarialiabad H, Schmidt E, Patsatsi A, Lim YL, Mosam A, Tasanen K, et al. Bullous pemphigoid. Nat Rev Dis Primers 2025; 11: 12. DOI: https://doi.org/10.1038/s41572-025-00595-5
Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2022; 36: 1689–1704. DOI: https://doi.org/10.1111/jdv.18220
Kridin K, Bergman R. Mortality in patients with bullous pemphigoid: a retrospective cohort study, systematic review and meta-analysis. Acta Derm Venereol 2019; 99: 72–77. DOI: https://doi.org/10.2340/00015555-2930
Chebani R, Lombart F, Chaby G, Dadban A, Debarbieux S, Viguier MA, et al. Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients. Br J Dermatol 2024; 190: 258–265. DOI: https://doi.org/10.1093/bjd/ljad369
Karakioulaki M, Eyerich K, Patsatsi A. Advancements in bullous pemphigoid treatment: a comprehensive pipeline update. Am J Clin Dermatol 2024; 25: 195–212. DOI: https://doi.org/10.1007/s40257-023-00832-1
Vassallo C, Somenzi A, De Amici M, Barruscotti S, Brazzelli V. Omalizumab as a corticosteroid-sparing agent in the treatment of bullous pemphigoid. Dermatol Ther 2022; 35: e15946. DOI: https://doi.org/10.1111/dth.15946
Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy 2020; 50: 5–14. DOI: https://doi.org/10.1111/cea.13491
Zhao L, Wang Q, Liang G, Zhou Y, Yiu N, Yang B, et al. Evaluation of dupilumab in patients with bullous pemphigoid. JAMA Dermatol 2023; 159: 953–960. DOI: https://doi.org/10.1001/jamadermatol.2023.2428
Planella-Fontanillas N, Bosch-Amate X, Jiménez Antón A, Moreno-Vílchez C, Guerrero MG, Blanes Martínez MDM, et al. Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series. Br J Dermatol 2025; 192: 501–509. DOI: https://doi.org/10.1093/bjd/ljae403
Seyed Jafari SM, Feldmeyer L, Bossart S, Simon D, Schlapbach C, Borradori L. Case Report: Combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid. Front Immunol 2021; 11: 611549. DOI: https://doi.org/10.3389/fimmu.2020.611549
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Romain Boisseau, Lea Scaramuzzino, Philippe Bernard, Christophe Bedane, Salome Fourmond
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
